Jazz Pharmaceuticals to acquire GW Pharmaceuticals in USd 7.2 billion
Jazz Pharmaceuticals plc and GW Pharmaceuticals plc announced the companies have entered into a definitive agreement for Jazz to acquire GW for USD 220.00 per American Depositary Share (ADS), in the form of USD 200.00 in cash and USD 20.00 in Jazz ordinary shares, for a total consideration of USD 7.2 billion, or USD 6.7 billion net of GW cash. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in the second quarter of 2021.